Seville, Spain

ICHNO 2026

Session

HPV or EBV related cancers
Poster
Impact of Smoking Status and Pack-Years on Outcomes in HPV-Associated Oropharyngeal Carcinoma Treated with Definitive (Chemo)Radiotherapy
Shao Hui Huang, Canada
-82
Highly-Multiplex Detection of Plasma Cell-Free High-Risk Human Papillomavirus DNA for Rare Genotypes
Janita Basit, Ireland
-83
Relationship between Epstein Barr Virus and nasopharyngeal cancer as a predictor of treatment response and recurrence
Cristian Arias, Spain
-195
Longitudinal Plasma ctDNA and Pathological Response Correlate with Clinical Outcomes in Oropharyngeal Cancer: Interim Analysis from the NECTORS Trial
Nivedita Kaorey, Canada
-252
Circulating tumor HPV DNA in HPV-associated oropharyngeal squamous cell carcinoma as a marker of recurrence: A retrospective cohort of 224 patients
Iwona Jabłońska, Poland
-258
Medial retropharyngeal lymph node involvement and recurrence rate in patients with nasopharyngeal carcinoma – a German multicenter analysis
Justus Kaufmann, Germany
-300
DNA-methylation as diagnostic and prognostic biomarker for oropharyngeal cancer – a proof-of-concept study
Wouter Huvenne, Belgium
-364
Comparison of NGS-based (HPV-Detect) and ddPCR plasma HPV-DNA assays for treatment response estimation in head and neck cancer in the INOVATE study
Shreerang Bhide, United Kingdom
-371
18F-FDG PET/CT dynamic Biomarkers in Metastatic Nasopharyngeal Carcinoma with PD-1 inhibitor
Beibei Xiao, China
-378
Characterization of the Intratumoral Microbiota in Non-Endemic EBV-Related Nasopharyngeal Carcinoma
Deborah Lenoci, Italy
-407
Phase 2 Trial of Ozuriftamab Vedotin (Oz-V), a conditionally binding ROR2-targeting ADC, in Patients with Treatment Refractory HPV+ OPSCC
Kyechin Chen, USA
-444
Postoperative cfHPV DNA Kinetics as a Potential Biomarker for Adjuvant Treatment Decision-Making in HPV-Positive OPSCC.
Radka Lohynska, Czech Republic
-475